Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease

Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease

IntroductionThe efficacy of enzyme replacement therapy (ERT) with alglucosidase alfa for infantile-onset Pompe disease (IOPD) is limited in some patients due to the development of high and sustained antibody titers (HSAT; ≥12,800).MethodsWe carried out detailed immunophenotyping of IOPD patients (n=...

Full description

Bibliographic Details
Main Authors:	Ankit K. Desai, P. Brian Smith, John S. Yi, Amy S. Rosenberg, Trevor D. Burt, Priya S. Kishnani
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Immunology
Subjects:	infantile-onset Pompe disease immunophenotyping anti-drug antibodies immune profiling immune activation enzyme replacement therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1301912/full

Similar Items

Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry
by: Priya S. Kishnani, et al.
Published: (2023-12-01)

An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation
by: Ankit K. Desai, et al.
Published: (2024-03-01)

A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation
by: Shiri Curelaru, et al.
Published: (2022-09-01)

Adenotonsillectomy should be avoided whenever possible in infantile-onset Pompe disease
by: Harrison N. Jones, et al.
Published: (2020-06-01)

Immune tolerance strategies in siblings with infantile Pompe disease — Advantages for a preemptive approach to high-sustained antibody titers
by: Elizabeth O. Stenger, et al.
Published: (2015-09-01)

Development of high sustained anti-drug antibody titers and corresponding clinical decline in a late-onset Pompe disease patient after 11+ years on enzyme replacement therapy
by: Katherine H. Kim, et al.
Published: (2023-09-01)

Characteristics of Pompe disease in China: a report from the Pompe registry
by: Yuying Zhao, et al.
Published: (2019-04-01)

The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan
by: Shu-Chuan Chiang, et al.
Published: (2020-04-01)

Importance of Timely Treatment Initiation in Infantile-Onset Pompe Disease, a Single-Centre Experience
by: Javier de las Heras, et al.
Published: (2021-11-01)

Enzyme replacement therapy and antibodies in late-onset Pompe disease
by: I. Schneider, et al.
Published: (2014-01-01)

Late-onset Pompe disease - literature review and summary of current knowledge
by: Karolina Jaskuła, et al.
Published: (2023-01-01)

Recommendations for Infantile-Onset and Late-Onset Pompe Disease: An Iranian Consensus
by: Farzad Fatehi, et al.
Published: (2021-09-01)

Multicentric Retrospective Evaluation of Five Classic Infantile Pompe Disease Subjects Under Enzyme Replacement Therapy With Early Infratentorial Involvement
by: Matteo Paoletti, et al.
Published: (2020-11-01)

A Liver Model of Infantile-Onset Pompe Disease Using Patient-Specific Induced Pluripotent Stem Cells
by: Takeshi Yoshida, et al.
Published: (2019-11-01)

Infantile‐onset Pompe disease with neutropenia: Treatment decisions in the face of a unique phenotype
by: Mary Riedy, et al.
Published: (2023-01-01)

Pompe disease in China: clinical and molecular characteristics
by: Jing Li, et al.
Published: (2023-12-01)

A Comprehensive Update on Late-Onset Pompe Disease
by: Beatrice Labella, et al.
Published: (2023-08-01)

Blepharoptosis in infantile onset Pompe disease: Histological findings and surgical outcomes
by: Yi-Hua Chen, et al.
Published: (2023-06-01)

Expert Group Consensus on early diagnosis and management of infantile-onset pompe disease in the Gulf Region
by: Zuhair Al-Hassnan, et al.
Published: (2022-10-01)

Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants
by: Mei-Yan Chan, et al.
Published: (2023-08-01)

Clinical laboratory experience of blood CRIM testing in infantile Pompe disease
by: Deeksha S. Bali, et al.
Published: (2015-12-01)

A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease
by: Barry J. Byrne, et al.
Published: (2017-08-01)

Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy
by: Chien-Yu Hsueh, et al.
Published: (2021-08-01)

Treatment Dilemma in Children with Late-Onset Pompe Disease
by: Martha Caterina Faraguna, et al.
Published: (2023-01-01)

Benefit of 5 years of enzyme replacement therapy in advanced late onset Pompe. A case report of misdiagnosis for three decades with acute respiratory failure at presentation
by: Mandat Maharaj, et al.
Published: (2022-09-01)

Late-onset Pompe Disease with Elevated Liver Transaminases: A Case Report
by: Maryam Bagheri, et al.
Published: (2019-12-01)

Pregnancy Outcomes in Late Onset Pompe Disease
by: Ozlem Goker-Alpan, et al.
Published: (2020-09-01)

Effects of immunomodulation in classic infantile Pompe patients with high antibody titers
by: E. Poelman, et al.
Published: (2019-03-01)

A Race Against Time—Changing the Natural History of CRIM Negative Infantile Pompe Disease
by: Punita Gupta, et al.
Published: (2020-09-01)

Infantile Pompe disease with intrauterine onset: a case report and literature review
by: Hongmin Xi, et al.
Published: (2022-11-01)

Quantitative muscle ultrasound and electrical impedance myography in late onset Pompe disease: A pilot study of reliability, longitudinal change and correlation with function
by: Lisa D. Hobson-Webb, et al.
Published: (2021-09-01)

Hypothyroidism in late-onset Pompe disease
by: Joseph Schneider, et al.
Published: (2016-09-01)

Are Anti-rhGAA Antibodies a Determinant of Treatment Outcome in Adults with Late-Onset Pompe Disease? A Systematic Review
by: Imke A. M. Ditters, et al.
Published: (2023-09-01)

Late-Onset Pompe Disease Presenting with Isolated Tongue Involvement
by: Jasem Al-Hashel, et al.
Published: (2022-03-01)

Muscle ultrasound in patients with late-onset Pompe disease identified by newborn screening
by: David G. Jackson, et al.
Published: (2023-09-01)

Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa
by: Chris Carter, et al.
Published: (2024-01-01)

Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort
by: Ankit K. Desai, et al.
Published: (2020-08-01)

New Insights into Gastrointestinal Involvement in Late-Onset Pompe Disease: Lessons Learned from Bench and Bedside
by: Aditi Korlimarla, et al.
Published: (2021-07-01)

Normal lymphocyte immunophenotype in an elderly population
by: Sâmia Macedo Queiroz Mota Castellão Tavares, et al.
Published: (2014-06-01)

Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy
by: Rossella Parini, et al.
Published: (2018-02-01)